CIP2A and lip and oral cavity carcinoma: Results from our study demonstrated that the 599 peptide could increase the intracellular bioavailability of siRNAs in oral cancer cells and effectively mediate the silencing of the targeted CIP2A oncoprotein with consequent inhibition of oral cancer cell invasiveness and anchorage-independent growth.